Takeda’s Iclusig Looks Set To Become SOC In First-Line Ph+ Acute Lymphoblastic Leukemia
Executive Summary
The drug beat out imatinib on efficacy while not drawing any increased concerns about safety, and an investigator told Scrip it should replace imatinib as first-line standard of care in the rare ALL subtype.